Madrigal (MDGL) has disclosed a new risk, in the Sales & Marketing category.
Madrigal faces a significant business risk due to its heavy reliance on a limited number of specialty pharmacies for the distribution of Rezdiffra in the United States. The potential loss or underperformance of these pharmacies could severely impact the company’s revenue stream, given that they account for all of it. Factors such as inaccurate inventory reporting, reduced sales efforts, or financial instability among these pharmacies could disrupt distribution and patient support. Additionally, any delay in replacing these pharmacies or modifying the distribution strategy could exacerbate these issues and further harm Madrigal’s business operations.
The average MDGL stock price target is $379.00, implying 6.50% upside potential.
To learn more about Madrigal’s risk factors, click here.